反応式
[Cl:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([CH2:12][CH:13]=O)[N:8]2[CH3:11])=[C:4]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)[N:3]=1.[CH3:21][C:22]1([OH:28])[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]1.C(OC)(OC)OC.C(O)(=O)C.C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+]>ClCCCl>[Cl:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([CH2:12][CH2:13][N:25]3[CH2:26][CH2:27][C:22]([CH3:21])([OH:28])[CH2:23][CH2:24]3)[N:8]2[CH3:11])=[C:4]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)[N:3]=1参加物
反応物 5
生成物 1
試薬・触媒・溶媒 1
実験手順
To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)acetaldehyde (200 mg, 0.68 mmol) in DCE (15 mL) was added 4-methylpiperidin-4-ol (117 mg, 1.01 mmol), trimethyl orthoformate (0.74 mL, 6.76 mmol) and acetic acid (0.04 mL, 0.68 mmol). The reaction mixture was stirred at room temperature for 1.5 h, sodium triacetoxyborohydride (187 mg, 1.35 mmol) was added and the resulting mixture stirred for a further 18 h. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH then the desired product eluted with 2 M NH3/MeOH in DCM. The resulting residue was purified by column chromatography (Si—PCC, 0-20% 2 M NH3/MeOH in DCM) to give the title compound as a colourless oil (45 mg, 17%). LCMS (Method H): RT=2.24 min, [M+H]+ 395.5
後処理
- stirringthe resulting mixture stirred for a further 18 h
- washwashed with MeOH
- washthe desired product eluted with 2 M NH3/MeOH in DCM
- customThe resulting residue was purified by column chromatography (Si—PCC, 0-20% 2 M NH3/MeOH in DCM)
出典と根拠
- ORDレコード
- ord-5ead96060361431491560dab1ae49695
- 出典データセット
- uspto-grants-2013_03
- 特許番号
- US08394796B2
関連ノート
読み込み中…